In 1999, the National Cancer Policy Board called attention to the quality of cancer care in the United States and recommended establishing a quality monitoring system with the capability of regularly reporting on the quality of care for patients with cancer.
INTRODUCTION
Despite considerable progress in its prevention and treatment, cancer remains a leading cause of morbidity and mortality in the United States. 1 Although the Institute of Medicine has called attention to problems with the quality of care in the United States 2-4 and additional reports have confirmed that the problems are widespread, [5] [6] [7] few reports have focused on the quality of care for patients with a diagnosis of cancer. In its 1999 report Ensuring the Quality of Cancer Care, the Institute of Medicine's National Cancer Policy Board (NCPB) concluded, "Based on the best available evidence, some individuals with cancer do not receive care known to be effective for their condition. The magnitude of the problem is not known, but the National Cancer Policy Board believes it is substantial." 8 To address these concerns and the paucity of data on the quality of care for patients with cancer, the NCPB recommended establishing a quality monitoring system with capability of routine reporting of results. Motivated by the NCPB report, a number of initiatives are underway to begin to measure and improve the quality of care of patients with cancer. Examples include the joint effort of the National Cancer Institute and the National Quality Forum to identify and evaluate quality measures for cancer care 9 ; the American Society of Clinical Oncology Quality Oncology Practice Initiative 10 ; the Oncology Demonstration Project sponsored by the Centers for Medicare and Medicaid Services 11 ; and the National Initiative for Cancer Care Quality (NICCQ), which is led by American Society of Clinical Oncology in collaboration with multiple oncology professional societies, patient advocates, and researchers. 12 In this report, we present the findings of the NICCQ, an in-depth study of the quality of care for patients with a new diagnosis of breast cancer or colorectal cancer in five different sites across the United States.
METHODS

Eligibility Criteria
Patients were considered eligible if they had a new diagnosis of stage I to III breast cancer or stage II to III colorectal cancer during 1998 and were registered in an American College of Surgeons (ACoS) -approved hospital cancer registry located in one of the following five metropolitan statistical areas (MSAs): Atlanta, GA; Cleveland, OH; Houston, TX; Kansas City, KS; and Los Angeles, CA. To be eligible, participants had to be 21 to 80 years old at diagnosis, English speaking, and alive when contacted to participate in this study approximately 4 years after diagnosis. Twenty-seven percent of colorectal cancer patients and 9% of breast cancer patients were found to be deceased when identified by participating ACoS hospital cancer registries and, thus, not eligible for our analytic sample. Males with breast cancer were excluded.
Hospital Registry Sampling and Recruitment
To achieve a sample size of approximately 400 patients with either breast or colorectal cancer from each MSA, we recruited all available ACoS-approved hospital cancer registries in four MSAs, and from Los Angeles, a probability sample of registries was selected from one of three strata defined by the number of breast and colorectal patients in 1998 (Ͻ 125, 125 to 250, and Ͼ 250 breast and colorectal cancer patients per year). We invited the participation of the hospital cancer registries by contacting the chair of each hospital's Cancer Committee andtheACoSCancerLiaisonandthenconvenedameetingineachMSAtoexplain the study. The study was approved by the institutional review boards at each of the participating institutions, RAND Corporation (Santa Monica, CA), and Harvard University (Cambridge, MA).
Patient Sampling and Recruitment
We used de-identified National Cancer Data Base (NCDB) data to select a sample of eligible patients from each participating hospital cancer registry (eight hospital registries that had not yet reported their 1998 data to the NCDB did their own patient selection using our sampling protocol). We sampled breast cancer patients from high-volume hospital registries to avoid overrepresenting patients from these facilities and selected all breast cancer patients from the remaining facilities. Because of the differing incidence of breast and colorectal cancer patients meeting our eligibility criteria, we selected all eligible patients with colorectal cancer.
Patient contact information was obtained from the local hospital cancer registries. Before contacting a patient, the physician of record was notified by mail of our intent to contact the patient for a research study. Unless a physician indicated that a patient should not be contacted, 2 weeks later the patient was mailed a letter explaining the study and a postage-paid postcard allowing the patient to opt out without further contact.
Development of Quality Measures and Data Collection Instruments
The NICCQ project team developed measures of the process of care within a set of domains representing important aspects of the care provided to patients with a cancer diagnosis (Table 1) . After reviewing existing quality indicators, 10 guidelines, 11-14 and review articles, 15-17 as well as randomized trials and other controlled studies of breast and colorectal cancer treatment identified through MEDLINE searches, we developed explicit quality measures to evaluate the initial management of breast and colorectal cancer patients. These measures specified eligible events-clinical care situations that should cause a clinician to recommend a particular diagnostic test, treatment, or other intervention based on the available medical science or general consensus among clinical experts. Proposed measures were reviewed to ensure clinical validity by an expert panel comprising clinical experts in breast and colorectal cancer, health services researchers, oncology nurses, and patient advocates. Our final set of quality measures included 36 breast cancer and 25 colorectal cancer quality measures. Examples of the quality measures are listed in Table 1 , and the full set is presented in the Appendix.
After selecting the measures, we developed both a patient survey and a medical record abstraction instrument to collect the specific data elements necessary for each quality measure. The survey included questions regarding patients' initial therapy and experiences, symptoms related to cancer or its treatment, and current quality of life. In addition, patients were asked to provide the names and addresses of all physicians who had provided their medical care since their diagnosis. Data obtained from the medical record included detailed information about the tumor characteristics, staging, referrals and decision making, initial cancertreatment,adjunctivemedications,andcomorbidconditions.Tobeeligible for an individual measure, the patient's medical records had to contain the records for the specialist generally responsible for providing the care. In addition, if the quality measure relied on information that is typically documented in a specific document (eg, pathology report), the patient's medical record had to contain this document for the patient to be eligible for inclusion in the measure. For example, to be eligible for the measure of "IF a patient is treated with chemotherapy, THEN body-surface area should be documented," a patient's medical record would need to contain the records of the medical oncologist and the chemotherapy flow sheet.
Data Collection
For each patient, full data collection required completion of a survey, consent for medical record review, a list of all physicians the patient had seen since diagnosis, and abstraction of relevant medical records. Two weeks after the initial invitation to patients, those who did not opt out were mailed a questionnaire, a medical record consent form, and a $10 incentive. After three follow-up mailings, we attempted to contact nonresponders to complete the survey by telephone.
We requested photocopies of consenting patients' ambulatory medical records from all cancer providers and primary care physicians as well as the inpatient record for colorectal cancer patients. Trained nurses abstracted all available records using a computer-based medical record abstraction instrument. When abstraction revealed cancer providers not reported by the patients, we requested those physicians' medical records and abstracted them as well.
Statistical Analyses
We calculated the mean percent adherence for breast cancer and colorectal cancer quality measures for each of the following five clinical domains (overall and stratified by MSA): (1) Diagnostic Evaluation, (2) Surgery, (3) Adjuvant Therapy, (4) Management of Treatment Toxicity, and (5) PostTreatment Surveillance; we also calculated the mean percent adherence for the following eight components of care: (1) Testing, (2) Pathology, (3) Documentation, (4) Referral, (5) Timing, (6) Receipt of Treatment, (7) Technical Quality, and (8) Respect for Patient Preferences. This method weights individual quality measures in the domain-level scores on the basis of prevalence of eligibility, determined by the number of times that patients were eligible for measures within a domain, which we refer to as the number of eligible events. In addition, we selected all measures with adherence less than 85% to compare the MSA-specific adherence because these measures are the most likely candidates for quality improvement interventions. We used 2 tests to compare the individual quality measures and the domain-level quality scores across MSAs. Analyses were conducted using SAS statistical software version 9.0 (SAS Institute, Inc, Cary, NC).
We adjusted for both hospital and patient nonresponse for the following hospital characteristics using ACoS data and patient characteristics using NCDB data: hospital ownership; oncology surgeon on staff; dummy variables for the individual participating hospitals; patient age, sex, race, education, insurance, employment, country of origin, and primary language; cancer type and stage; and cancer treatment. Although we report weighted results because we believe they are most representative, weighting did not affect the direction or statistical significance of any reported results.
RESULTS
Recruitment of Cohort
Of the 94 hospital cancer registries we invited to participate in NICCQ, 65 registries (69%) agreed. Among 3,775 eligible patients, 2,366 responded to the survey (63%); and, of these patients, 2,002 (85%) consented to have their medical records reviewed. We obtained at least one medical record for 98% of consenting patients, and the records of 88% of consenting patients (n ϭ 1,765) were adequate for abstraction. Our final analytic sample included 47% of the eligible patients. The characteristics of the analytic cohort are listed in Table 2 .
Quality of Care
Among the patients with breast cancer (n ϭ 1,287), there were 20,291 eligible events specified by 36 quality measures (Table 3) . On average, patients received 86% of recommended care (95% CI, 86% to 87%). Among the domains of care assessed, Diagnostic Evaluation had the greatest number of eligible events (n ϭ 9,887), and Management of Treatment Toxicity had the fewest (n ϭ 378). Adherence to recommended care within domains ranged from 73% (95% CI, 69% to 78%) for Management of Treatment Toxicity to 94% (95% CI, 92% to 95%) for Post-Treatment Surveillance. Adherence to recommended care across the different components of care ranged from 13% (95% CI, 7% to 21%) for Referral to 60% (95% CI, 57% to 62%) for Documentation to 96% (95% CI, 95% to 97%) and 97% (95% CI, 96% to 97%) for Receipt of Treatment and Testing, respectively.
Among the patients with colorectal cancer, there were 4,538 eligible events based on the 25 colorectal cancer measures (Table 3) . On average, patients received 78% of recommended care (95% CI, 77% to 79%). Again, the greatest number of eligible events was in Diagnostic Evaluation (n ϭ 1,635). The domain of Post-Treatment Surveillance had the smallest number of eligible events (n ϭ 478). Domain-specific adherence ranged from 50% (95% CI, 46% to 55%) for Post-Treatment Surveillance to 93% (95% CI, 91% to 95%) for Surgery. Adherence to recommended care across the different components of care ranged from 57% (95% CI, 53% to 62%) for Respect for patient references and 59% (95% CI, 50% to 68%) for Referral to 93% (95% CI, 91% to 94%) for Pathology.
Variation in Quality of Care Across NICCQ MSAs
The overall mean adherence to the 36 breast quality measures ranged from 82% to 87% across the five MSAs (P Ͻ .001, Table 4 ), but no MSA seemed to consistently provide better quality of care across all domains. Within domains, the greatest variation across MSAs was observed for Surgery (80% to 90%, P Ͻ .001). Significant variation across MSAs was also observed for the domains of Diagnostic Evaluation (P Ͻ .01) and Adjuvant Therapy (P Ͻ .05). In colorectal cancer, where we had a smaller sample size, the variation across MSAs was not statistically significant.
Adherence to quality measures was less than 85% for 18 of the 36 breast cancer measures, and there was significant variation in the percent adherence across MSAs for seven of the quality measures ( Table 5) . As much as a two-fold difference in adherence was observed for some measures across MSAs. For example, among patients treated with chemotherapy, the planned dose was consistent with published regimens for 58% of patients; however, this ranged from 29% to 74%, when weighted for hospital and patient nonresponse (P Ͻ .001). Notably, six of the measures with less than 85% adherence pertained to documentation of key clinical factors believed to be essential to providing appropriate cancer care, such as components of disease stage and patient's body-surface area.
The percent adherence was less than 85% for 14 of the 25 colorectal cancer measures; however, only one quality measure demonstrated statistically significant variation across the MSAs (Table 6 ). In 
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Fifteen patients were missing data regarding education. †Forty-nine patients were missing data on stage.
patients with stage II or III rectal cancer, we found that only 66% received radiation therapy as recommended; this varied by MSA from 58% to 92% (P ϭ .05).
DISCUSSION
Our results suggest that patients with breast cancer receive 86% of recommended care, whereas patients with colorectal cancer receive 78% of recommended care. Adherence to several quality measures approached 100%, demonstrating that excellent quality of care is achievable. Yet, despite high adherence to many measures of the quality of cancer care, we observed less than 85% adherence for almost half of the quality measures, and for many of these measures, there was substantial variability in quality across the five metropolitan areas. How do we put these results in context? Our results can be compared with a growing literature that addresses the quality of care of patients with chronic medical conditions, as well as prior studies that describe the patterns of care for patients with cancer. For example, two recent national studies, using methodology similar to that of NICCQ, suggest that the quality of care for cancer may be better than that observed for other chronic medical conditions. In one study, 73% of Medicare beneficiaries received health care services specified by one of 24 quality measures addressing heart disease, stroke, and pneumonia. 5 Another recent study of the general population in 12 metropolitan areas of the United States concluded that participants received approximately 55% of recommended care for a wide variety of medical conditions. 6 In contrast, the NICCQ results suggest that higher percentages of patients with breast and colorectal cancer receive recommended care.
Compared with prior studies of cancer care summarized by the NCPB, our results show strikingly higher adherence to processes of care believed to be essential for improving the outcomes of patients with breast and colorectal cancer. There are several possible explanations for this difference. In contrast to most prior studies, NICCQ used explicit quality measures with clinically detailed eligibility criteria. 18, 19 When simple utilization rates (eg, receipt of tamoxifen in nonmetastatic breast cancer patients) are used to estimate receipt of recommended care, quality of care may seem artificially low because many patients included in the analysis may not really be eligible for the specified care (eg, patients whose tumors do not express the estrogen NICCQ used patient self-report data along with data abstracted from multiple outpatient medical records (an average of 3.6 records per patient). The NCPB based its conclusions about the state of cancer care in the United States primarily on studies of existing administrative records, insurance claims, and cancer registry data. Such data frequently lack the clinical detail necessary to determine whether a patient is truly eligible for a particular intervention 8, 20, 22 and may under-report the treatments provided, especially when delivered in the ambulatory setting. [23] [24] [25] In fact, the few studies that used analogous methods to NICCQ to evaluate the quality of cancer care have reported better than 80% adherence. 6, [25] [26] [27] If the quality of care for cancer is indeed higher than for other medical conditions, what factors might contribute to the difference? It may be that the urgency of a new diagnosis of cancer focuses the attention of patients and providers on assuring treatment in a way that chronic diseases, especially silent ones such as hypertension or diabetes, cannot. Differences in the configuration of treatment teams, reimbursement for services, training, and public attention may also play a role.
This study assessed performance on a wide variety of quality metrics derived from the clinical literature. All of the measures underwent review and refinement by a multidisciplinary expert panel comprising clinical experts in breast and colorectal cancer, health services researchers, oncology nurses, and patient advocates. Many measures were linked by scientific evidence with improved patient outcomes. For example, randomized trials have demonstrated improved survival with 5 years of tamoxifen therapy in women with hormone receptorpositive breast cancer. In other instances, the measures focused on operational issues that clinical experts viewed as necessary to the delivery of high-quality care. For example, documentation of patient body-surface area in the medical record of the medical oncologist delivering chemotherapy is necessary for the physician to determine the appropriate dose and for the nursing or pharmacy staff to verify the prescribed dose to ensure patient safety.
Given adherence rates of less than 85% on almost half of the quality measures, our results suggest many opportunities to improve the quality of cancer care. Of concern, we found that, although most patients seemed to be receiving adjuvant chemotherapy when indicated, patients were often not prescribed a dose of the chemotherapy that was consistent with published regimens, and many began therapy more than 8 weeks after surgery. In addition to focusing on improving the quality of adjuvant chemotherapy delivery, our results suggest that quality improvement efforts should target management of treatment toxicity; advising patients about treatment options, especially when patient preference is a key factor in the decision-making process (ie, type of breast surgery and breast reconstruction after mastectomy); and improving documentation of key information regarding patients' cancer and treatment that may be needed by many other clinicians involved in the patients' care.
Our findings should be viewed in light of several limitations of our study design. First, our study was limited to patients with stage I to III breast cancer and stage II to III colorectal cancer. The quality of care for patients with other types of cancer and stages of disease may be different. Second, our quality measures reflect the weight of both scientific evidence and expert opinion. Variability in the strength of evidence underpinning individual measures could affect the pattern of performance we found. Third, we were unable to include patients who could not complete a survey in English or who died before study enrollment, two groups for whom the quality of care may be lower. The omission of patients who died within the first few years of diagnosis may be of particular concern because premature death could be an outcome of poor quality of care. If patients who die receive care that that is of lower quality than that received by survivors, then our results may overestimate the quality of care of colorectal cancer patients because 27% of patients reported by the registries were deceased when identified by NICCQ. However, only 9% of breast cancer patients were deceased 4 years after diagnosis, so the exclusion of decedents from our sampling frame is not likely to have had a large effect on our estimate of the quality of breast cancer care. Fourth, nonparticipation of hospitals and patients may also limit the generalizability of our results. Our final sample included 47% of eligible patients, which is comparable to other studies that have obtained survey and consent to review medical records from population-based samples. 6 We used nonresponse weights to account for the different distribution of race/ ethnicity and age in our final sample, and our results did not change substantively. Nevertheless, our results could still be biased if nonresponders were less likely to get appropriate care. Finally, although this study included data from both patient self report and abstraction from the medical records of all the physicians providing cancer care to patients, recall bias and missing documentation may have led to under-reporting of care that was actually provided. Despite these limitations, we believe that our results provide a useful benchmark for other efforts to evaluate the quality of cancer care.
To our knowledge, this the first report of a comprehensive evaluation of the quality of care for patients with cancer. Although our results imply that the quality of initial management of patients with breast and colorectal cancer in the United States is often consistent with evidence-based practice, care is still not perfect. Viewed from the perspective of the patient with breast or colorectal cancer, a person with a new diagnosis of cancer has approximately a one in five chance of failing to receive elements of cancer care consistent with the best evidence in the literature and expert-defined standards of clinical practice. Important opportunities to improve care exist. Our results may provide guidance for professional societies and clinicians involved in cancer care on how best to improve the care of patients with cancer. Figure 1 , in the "Arm 2" column, the second course of chemotherapy should not have read "(2 cycles every 3 weeks)." Under the "Arm 3" column, the first course of chemotherapy should not have read "(2 cycles every 3 weeks)."
The online version has been corrected in departure from the print. Table 3 misattributed the results for the following components of care: Timing, Receipt of treatment, Technical quality of treatment, and Respect for patient preferences. The corrected table has been reprinted in its entirety online. Correspondingly, in the Results section, the last sentence under the Quality of Care heading should have read, "Adherence to recommended care across the different components of care ranged from 57% (95% CI, 53% to 62%) for Respect for patient preferences and 59% (95% CI, 91% to 94%) for Referral to 93% (95% CI, 91% to 94%) for Pathology." Tables 5 and 6 reported the unweighted results for individual MSA adherence rates, but should have given the weighted results for overall adherence and by MSA. The corrected tables have been reprinted in their entirety online. Correspondingly, in the Results section, the third sentence in the second paragraph under the Variation in Quality of Care Across NICCQ MSAs heading should have read, "For example, among patients treated with chemotherapy, the planned dose was consistent with published regimens for 58% of patients; however, this ranged from 29% to 74%, when weighted for hospital and patient nonresponse (P Ͻ .001)."
The online version has been corrected in departure from the print.
